South San Francisco, Calif., January 5, 2023 – Asher Biotherapeutics, Inc. (Asher Bio), a biotechnology company focused on developing therapies to precisely engage specific immune cells to fight cancer, today announced the appointment of Elaine Sun to its Board of Directors (the Board). Ms. Sun currently serves as Chief Operating Officer and Chief Financial Officer of Mammoth Biosciences, Inc. (Mammoth Biosciences).
“We are excited to welcome Elaine to our Board, as she brings exceptional strategic, operational, and financial experience and leadership to our organization,” said Craig Gibbs, Ph.D., Chief Executive Officer of Asher Bio. “Elaine’s impressive track record of creating value in the biopharmaceutical industry and fostering the growth of both early- and late-stage biotechnology companies will be a tremendous resource for Asher Bio as we advance our pipeline of precision immunotherapies into the clinic.”
“I am impressed with the potential of Asher Bio’s cis-targeting platform to transform immunotherapy and the team’s tremendous progress in advancing its pipeline candidates into the clinic. The company’s ongoing development of potential therapies intended to precisely engage specific immune cells to address disease areas with high unmet need positions Asher Bio to stand out in the field and potentially deliver important new medicines that could lead to meaningfully improved treatment options for patients,” said Ms. Sun. “I am honored to join Asher Bio’s Board and look forward to working with the management team and other Board members at this pivotal stage for the company.”
Ms. Sun has more than twenty-five years of experience in life sciences. Prior to her role as Chief Operating Officer and Chief Financial Officer at Mammoth Biosciences, Ms. Sun served as Senior Vice President and Chief Financial Officer at Halozyme Therapeutics, Inc. (Halozyme). Prior to Halozyme, she served as Chief Financial Officer and Chief Strategy Officer at SutroVax, Inc. (now known as Vaxcyte, Inc.). Over the course of these roles, Elaine provided leadership to rapidly growing organizations, and led a number of functions including finance, accounting, information technology, site operations, and commercial business units. Previously, Ms. Sun served as Managing Director and Head of West Coast Healthcare for Evercore Partners and Managing Director at Merrill Lynch & Co., Inc. During her career, she has led and played key roles in a broad range of transactions, including multiple mergers, acquisitions, and financings, valued in excess of $50 billion. Ms. Sun currently serves on the board of directors of Dynavax Technologies Corporation and previously served on the board of directors of Cirius Therapeutics. She received her B.A. from Wellesley College and M.B.A from Harvard Business School.
About Asher Bio
Asher Bio is a biotechnology company developing therapies to precisely engage specific immune cells to fight cancer, chronic viral infection and autoimmune disease. We utilize our proprietary cis-targeting platform to develop therapies engineered to overcome limitations of other immune-based treatments by selectively activating specific immune cell types with validated disease fighting functionality. Our candidates feature an antibody connected to a modified immunomodulatory protein, such as a cytokine. Our candidate design is intended to enable our candidates to selectively activate the desired immune cells and not other cells that contribute to toxicity or immune suppression. Asher Bio was founded by Ivana Djuretic and Andy Yeung with support from Third Rock Ventures and is located in South San Francisco. For more information, please visit www.asherbio.com and follow us on Twitter @AsherBio and on LinkedIn.
Media Contact
Kathryn Morris, The Yates Network
914-204-6412
kathryn@theyatesnetwork.com
Investor Contact
Hannah Deresiewicz, Stern Investor Relations, Inc.
212-362-1200
hannah.deresiewicz@sternir.com
This links to an external website.